RIGI and neoplasm: Furthermore, recent work has revealed that RIG-I is required for adequate response to anti-CTLA-4 treatment by inducing caspase-3-mediated tumor cell death, following which the tumor-associated antigens are processed and presented, leading to a robust CD8+ T cell-mediated adaptive immune response [134].